Although acquired uniparental disomy (aUPD) has been reported in relapse acute myeloid leukemia (AML), pretransplant aUPD involving chromosome 6 is poorly documented. Such events could be of interest because loss of heterozygosity (LOH) resulting from aUPD in leukemic cells may lead to erroneous results if HLA typing for hematopoietic stem cell donor searches is performed on blood samples drawn during blastic crisis. We report here six AML patients whose HLA typing was performed on DNA extracted from peripheral blood obtained at diagnosis. We observed LOH involving the entire HLA region (three patients), HLA-A, B, C (two patients) and HLA-A only (one patient). An array-comparative genomic hybridization showed that copy number was neutral for all loci, thus revealing partial aUPD of chromosome 6p21. When HLA typing was performed on remission blood samples both haplotypes were detected. A 3 --4% LOH incidence was estimated in AML patients with high blast counts. Based on DNA mixing experiments, we determined by PCR sequence-specific oligonucleotide hybridization on microbeads arrays a detection threshold for HLA-A, B, DRB1 heterozygosity in blood samples with o80% blasts. Because aUPD may be partial, any homozygous HLA result should be confirmed by a second typing performed on buccal swabs or on blood samples from the patient in remission.
INTRODUCTION
Loss or downregulation of HLA class I antigens may allow tumor cells to escape T-cell immunosurveillance. HLA loss of heterozygosity (LOH), or haplotype loss, is a frequent event in a variety of solid tumors 1,2 but seems to be rare in hematological cancers. In a study on 25 acute myeloid leukemia (AML) patients at diagnosis, HLA class I expression was found to be preserved in all cases. 3 The potential of adoptive T-cell immunotherapy by donorlymphocyte infusions for treating leukemic patients has stimulated interest in HLA class I expression on leukemic cells that could impact on the efficacy of donor-lymphocyte infusions. An HLA and microsatellite genotyping analysis of 44 samples of freshly isolated leukemic blasts did not reveal any case of haplotype loss, although a downregulation of HLA class I expression was observed in 9.1% of the patients samples. 4 Recently, a loss of mismatched HLA has been demonstrated in a significant proportion of AML patients relapsing after donor-lymphocyte infusions following transplantation with hematopoietic stem cells from haploidentical donors. 5 --7 As revealed by single-nucleotide polymorphism array analysis, HLA loss was copy-number neutral and thus resulted from acquired uniparental disomy (aUPD), 5 a chromosomal aberration that occurs when both copies of a chromosome or a chromosomal segment originate from one parent (reviewed Tuna et al. 8 ). Chromosomal segregation or non-disjunction error in mitosis, or mitotic recombination in the S/G2 phase of the cell cycle can account for the occurrence of aUPD. 8 The role of copy number mutants in tumor-suppressor genes and oncogenes in leukemia outcome has stimulated detailed analyses of aUPD as a mechanism underlying molecular aberrations affecting disease outcome. Although cancers such as retinoblastoma, rectal, basal cell or MUTYH-associated polyposis carcinomas exhibit high percentages of aUPD (50 --85%), the rates are much lower in AMLs. 8 Following smaller scale studies, 9 --12 a single-nucleotide polymorphism microarray study on 454 AML patients has disclosed aUPD in 17% of the samples. 13 In this study, the authors reported a non-random distribution of aUPD more specifically affecting chromosomes arms 13q, 11p and 11q. In addition, losses accounted for 15% and gains for 12% of the AML samples. A more recent genome-wide single-nucleotide polymorphism analysis of 157 cytogenetically normal AML adult patients also reported a 17% aUPD incidence. 14 We report herein six patients whose HLA typing was performed on peripheral blood lymphocytes obtained from AML patients in acute phase at diagnosis and led to an apparent LOH as determined by PCR sequence-specific oligonucleotide (SSO)/ sequence-based typing (SBT) using locus-specific primers. Comparative genomic hybridization (CGH) on microarrays did not reveal any copy number variation of HLA loci at 6p21 that could account for the loss of haplotypes, and thus allowed to confirm that the HLA homozygosity was due to aUPD. In addition, through in-vitro DNA mixing experiments, we have determined a threshold for the detection of HLA alleles by the reverse hybridization on microbeads arrays (luminex technology).
PATIENTS AND METHODS
The six patients reported in this study (Table 1) Genomic DNA was extracted using the GenoM6 automat (Qiagen cartridge, Qiagen GmbH, Hilden, Germany), or by spin columns on the QIAcube (Qiagen GmbH), or by a manual salting out method.
HLA typing was performed by PCR-SSO hybridization on microbeads arrays (One Lambda HD kits, Canoga Park, CA, USA; or Gene-Probe kits, San Diego, CA, USA), by PCR sequence-specific primers (SSPs) (Genovision, West Chester, PA, USA) and by biallelic PCR-SBT (Abbott Molecular Park, Chicago, IL, USA).
Array-CGH (aCGH) was performed on the probands using the Human Genome CGH Microarray Kit 180K (Agilent Technologies, Palo Alto, CA, USA) with 13 kb overall median probe spacing giving an average resolution of 30 kb. Briefly, 1 mg of patient and a sex-matched pooled reference DNAs (Promega Corporation, Madison, WI, USA) were processed according to manufacturer's protocol. Fluorescence was scanned in a dual-laser scanner (Agilent DNA microarray scanner G2565CA; Agilent Technologies) and the images were extracted and analyzed with Agilent Feature Extraction software (v9.5.3.1) and CGH Analytics software (v3.5.14; Agilent Technologies, Santa Clara, CA, USA), respectively. Changes in test DNA copy number at a specific locus are observed as the deviation of the log-ratio value from a modal value of 0. The normal range is indicated by black dots (Figure 2 ), whereas a loss is indicated for probes with a log-ratio value of À1 (green dots in Figure 2) , and a gain is indicated by probes with a log-ratio value 40.6 (red dots in Figure 2 ). At least X2 contiguous copy number alterations are considered as significant. We reported herein only copy number variations located in the HLA region at 6p21. Genomic content analysis was performed by aCGH for female and male reference DNA samples to identify potential imbalances in the HLA region of interest. Both reference DNA samples were shown to be positive for the HLA-DRB5 locus by PCR-SSP genotyping.
DNA mixing experiments were set up by mixing two DNA samples homozygous for the HLA-A, B, DRB1 loci. DNA#1 (A*01:01; B*08:01; DRB1*03:01) and DNA#2 (A*32:01; B*35:01; DRB1*11:01) were diluted at 20 ng/ml and then mixed at different ratios: 100 --0%, 90 --10%, 85 --15%, 80 --20%, 70 --30% and 50 --50%. In all, 2-ml samples (40 ng) of each mix were amplified with locus-specific primers as described by the supplier and typed by the microbeads arrays (luminex) in parallel to routine clinical samples (using One Lambda LabType RSSO1A, RSSO1B, RSSO2B1 reagents). For each HLA-A,B,DRB1 allele that could not be assigned all allele-specific negative probes were listed and the mean fluorescence intensity values compared with the cutoff values provided by the manufacturer. Excluding beads that are positive with both alleles, a total of 53 allele-specific beads were analyzed: beads 27, 56 In addition, a DNA mixing experiment was performed by using homozygous DNA#1 (A*01:01; B*08:01; DRB1*03:01) and heterozygous DNA#3 (A*01:01, A*11:01; B*08:01, B*35:01; DRB1*03:01, DRB1*11:04). Detection of the A*11:01, B*35:01 and DRB1*11:04 alleles present at a 10, 15, 20, 30 and 50% ratio was determined by the evaluation of 29 allele-specific beads using the luminex typing assay. Beads 27, 31, 36, 63, 64, 77, 87, 525, 552, 554, 583 were specific for A*11:01; beads 71, 87, 514, 529, 544, 567, 568, 590, 594 were specific for B*35:01; and beads 1, 28, 29, 57, 64, 69, 73, 83, 89 were specific for DRB1*11:04. Because the interpretation software of the luminex typing system can assign only two HLA alleles, mixing experiments could only be performed with between AA and BB or AB haplotypes.
RESULTS
HLA typing data DNA typing of three AML patients at diagnosis (ELHM, FDM and JH) revealed a complete HLA-A, B, C, DRB1, DQB1 homozygosity (Table 2 , rows 1, 3 and 9), as determined by reverse PCR-SSO hybridization on microbeads arrays (luminex technology). Biallelic PCR-SBT revealed HLA class I homozygosity in two additional patients (PA and ND) ( Table 2 , rows 5 and 7), whereas they were heterozygous for HLA-DRB1 as shown by PCR-SSO hybridization on microbeads arrays. A sixth patient tested at diagnosis revealed homozygosity at HLA-A with a rare A*02:05 allele, but heterozygosity at all other loci (Table 2, row 11). Patients showed a percentage of blasts ranging from 85 to 95% (Table 2 ) when blood samples were drawn for HLA typing in view of a hematopoietic stem cell donor search. For patients DMF, PA and JH, the family pedigree immediately suggested an apparent LOH. A microsatellite analysis using four informative microsatellites markers in the HLA region independently confirmed LOH in patient ELHM (data not shown). When retyping was subsequently performed for all six patients on blood samples drawn in remission, complete HLA class I and II heterozygosity was disclosed (Table 2, When HLA typing was performed at diagnosis by the PCR-SSP method the second allele could be readily detected, although the primer mixes specific for the minor allele resulted in systematically weaker amplifications, as shown for HLA-DPB1 typing of patient Abbreviations: AML, acute myeloid leukemia; LOH, loss of heterozygosity.
Pretransplant HLA mistyping in diagnostic samples of AML patients V Dubois et al DMF ( Figure 1 ). For patient PA monoallelic sequencing, as opposed to biallelic sequencing, revealed complete HLA class I heterozygosity (data not shown). Interestingly in the case of patient CJ even monoallelic SBT did not allow to detect the A*02:01 allele when performed on the DNA extracted from patient's blood sample obtained at diagnosis, presumably because the heterozygosity concerned two alleles within the same amplification group (A*02).
Array-CGH To detect putative deletions in the major histocompatibility complex region, the six patients' DNA samples were analyzed by aCGH as described in Materials and Methods. No evidence of a homozygous deletion at any of the HLA-A, B, C, DRB1, DQB1, DPB1 loci could be detected (Figures 2a and b) , showing that HLA loss at 6p21 was copy-number neutral and can only be interpreted as a result of aUPD. Interestingly, patients DMF, ND ( Figure 2a ) and CJ ( Figure 2b ) showed a small homozygous deletion of a DNA segment (6p21.32, rs32480027 --32521929) corresponding to the DRB5/DRB6 loci according to NCBI build 37 (see HLA typing in Table 2 ), as revealed by 2 --3 contiguous probes showing log-ratio values between À1.5 and À2. The absence of DRB5 was expected since DMF blast cells were homozygous for DRB1*14 and ND blast cells heterozygous DRB1*03,*11. For patients ELHM ( Figure 2a ) and JH (Figure 2b ), whose blast cells would also be expected to lack the DRB5 locus, a signal was obtained with one probe only and thus not considered as significant by the software. Patient PA blasts that were typed as DRB1*08,*15 (Table 2 ) are expected to lack the DRB5 locus on one haplotype only. Indeed, aCGH indicates a signal corresponding to a heterozygous deletion (circle in Figure 2b ). In addition, a few small microdeletions were observed at 6p21 in four of the six patients. Patient DMF (Figure 2a ) has a heterozygous deletion at the HLA-B locus (6p21.33, rs31287351 --31326021), which may result from some mosaicism in the blast population, according to ratio values around À0.8. Patient PA (Figure 2b ) has a homozygous deletion at 6p22.1 centromeric to HLA-A (rs29854870 --29873933). Patient JH (Figure 2b) has two deletions at 6p22.1 very close to the HLA-A gene, one homozygous deletion (rs29854870 --29873933) encompassing the HCG2P7 and HLA-H genes and a heterozygous deletion (rs29887268 --29896657) comprising the HCG4P6 gene. An aCGH test performed on the mother of patient JH (data not shown) allowed to conclude that these microdeletions were not inherited from the mother. Patient CJ has a short duplication (rs29842826 --29918779) close to HLA-A (Figure 2b) . Thus, in addition to aUPD which lead to complete or partial HLA homozygosity, the blast cells of these patients showed a DNA content with microdeletions or duplications, either of parental origin, or occurring de novo 15 at the blastic level.
DNA mixing experiments
To define more precisely a cutoff limit for the detection of a heterozygous DNA present in a fraction of the cells by the luminex technology, the following mixing experiments were performed. First, two HLA-A, B, DRB1 homozygous DNA samples (DNA#1: HLA-A*01:01; B*08:01; DRB1*03:01 and DNA#2: HLA-A*32:01; B*35:01; DRB1*11:01) were mixed at a 90 --10%, 85 --15%, 80 --20%, 70 --30% and 50 --50% ratio. Each mix was then tested by the luminex assay and mean fluorescence intensity values analyzed for each allele-specific bead. The results for all negative beads are shown in Table 3 and are representative of three experiments. For example, of the seven A*01:01-specific probes, three were positive at all dilutions (beads 74, 75, 95), whereas four probes (beads 27, 56, 61, 67) were negative at a 10/90% DNA ratio, but positive at ratios X15%. Altogether, of the 53 beads that were specific for the 6 HLA-A,B,DRB1 alleles, 23 (41.5%) were negative at a 10/90% DNA ratio. The negative probes were on average 20% below the cutoff (range o1 --40%) with somewhat larger differences for the HLA-Bspecific probes. At a 15% ratio the luminex assay allowed to assign both HLA alleles for each locus, although for three combinations the heterozygous result was assigned by the HLA Fusion software (One Lambda) with a single false negative bead (5.6% of the specific beads): bead 17 for A*32:01, bead 521 for B*08:01 and bead 514 for B*35:01 (Table 3) . For the assignment of B*35 at a 15% ratio, three probes were negative but very close to the cutoff level (20%, 8% and 13% below, respectively). These results show that the detection level of the luminex microbeads assay for heterozygous combinations is 15% in mixing experiments of two homozygous DNA samples. Taking into account the double amount of the minor DNA template due to homozygosity we calculate that the HLA misassignment threshold of 10% would correspond to a 20% ratio of normal heterozygous cells over 80% leukemic blasts with LOH. This result was then confirmed by a mixing experiment using the homozygous HLA-A Figure 3 shows the hybridization patterns of five representative A*11:01-specific beads. For the detection of the A*11:01 allele, seven beads were negative at a 15% ratio (for example, beads 27,63,64,554 in Figure 3 ), four at a 20% ratio (for example, bead 554 in Figure 3 ) and only one at a 30% ratio (data not shown). The combined luminex analysis of the 29 A*11:01-, B*35:01-and DRB1*11:04-specific Abbreviation: MFI, mean fluorescence intensity. At a 10/90% ratio, none of the six HLA-A, B, DRB1 alleles could not be assigned because of 23 negative beads of a total of 53 allele-specific beads. At a 15/85% ratio, the two alleles at each locus could be assigned by modifying the cutoff of a single probe except for B*35 (three negative probes but close to the cutoff value). In the second column, the cutoff values for bead positivity are represented as indicated by the supplier.
a At a 10/90% ratio, the MFI values for each bead when they were below the cutoff value are shown. b At a 15/85% ratio, the MFI values for each bead when they were below the cutoff value are shown, all MFI values above the cutoff are indicated as pos. 30%   64   100  90  80  70  60  50  40  30  20  10   100  90  80  70  60  50  40  30  20  10   100  90  80  70  60  50  40  30  20  10   100  90  80  70  60  50  40  30  20  10   100  90  80  70  60  50  40  30  20  10   100  90  80  70  60  50  40  30  20  10   100  90  80  70  60  50  40  30  20  10   100  90  80  70  60  50  40  30  20  10   100  90  80  70  60  50  40  30  20  10   100  90  80  70  60  50  40  30  20  10   100  90  80  70  60  50  40  30  20  10   100  90  80  70  60  50  40  30  20  10   100  90  80  70  60  50  40  30  20  10   100  90  80  70  60  50  40  30  20  10   100  90  80  70  60  50  40  30  20  10   100  90  80  70  60  50  40  30  20  10   100  90  80  70  60  50  40  30  20  10   100  90  80  70  60  50  40  30  20  10   100  90  80  70  60  50  40  30  20  10   100  90  80  70  60  50  40  30  20  10 63 554 583 Of the 11 A*11-specific beads, 9 were negative at a 10% ratio, 7 at a 15% ratio, 4 at a 20% ratio and 1 at a 30% ratio. HLA-A heterozygosity could only be unambiguously assessed in samples with 420% DNA#3. Red bars correspond to the samples tested in the mixing experiments. Horizontal line represents the cutoff value as defined by the manufacturer. y axis: MFI. Other clinical samples have been analyzed in parallel (green bars). beads showed that the detection level of the heterozygous DNA was in the range of 20 --30% with 19 (66%) positive beads at a 20% ratio and 25 (86%) positive beads at a 30% ratio. Therefore, loss of a given HLA allele would go undetected by the luminex technique if tested on a blood sample containing X80% blasts.
DISCUSSION
We describe here six AML patients with LOH in the HLA region due to aUPD as shown by aCGH assays performed on the blood samples collected at diagnosis. Although the patients originated from different centers, the results reported in this study show that copy-neutral LOH involving chromosome 6 may not be an exceptional event. Furthermore, if aUPD concerns only part of the HLA loci, such as observed in three patients, its frequency may also be underappreciated by the HLA laboratories. As a minimal frequency estimation, we can rely on two studies. In the largest study performed so far on 454 AML patients, only one aUPD event involving 6p21 was reported (Supplementary Figure 2F , Gupta et al. 13 ), which would represent 0.22% of all AML patients. In the same study, two gains of the entire chromosome 6 (0.44%) were observed, but such alterations are not expected to affect the HLA types. In the second study on 157 cytogenetically normal AML patients, aUPD on 6p21 was observed in two (1.27%) patients ( Figure 1a , Bullinger et al. 14 ) . Very recently three cases of LOH leading to HLA homozygosity have been described representing about 4% of patients suffering of myeloid malignancies tested in this center. 16 Although mechanisms contributing to the LOH were not addressed in this study, we predict that aUPD may account for these LOH cases.
In our study, the actual frequency of LOH among AML patients is difficult to assess precisely, because the six cases have been detected in five different laboratories with four of them in the last year and two in previous years. Also, the algorithm of requesting patient's HLA typing straight at diagnosis or in remission varies depending on the transplant centers connected to the five HLA laboratories. We could estimate that 150 --200 AML patients, whose blood samples were drawn at diagnosis, have been tested in the timeframe in which the six cases were detected. Therefore, a 3 --4% LOH incidence can be calculated as a minimal estimate, which is very close to the recently reported rate. 16 aUPD involving 6p21 in pretransplant samples may thus be more frequent than expected. The risk of HLA allele misassignment would even be higher if aUPD does not involve the entire major histocompatibility complex thereby leading to only partial HLA homozygosity, such as observed in patient CJ. An apparent LOH will be readily detected by the segregation analysis upon family genotyping, as observed in three of the patients described in this study. In case no family member is available, the second control typing, as is mandatory for any patient by the laboratory standards for histocompatibility testing, 17 should be performed on a buccal swab, or on a blood sample from the patient at remission. Alternatively, any homozygous HLA typing result obtained in blastic cells should be verified by PCR-SSP.
The HLA typing results (Table 2) obtained by PCR-SSO reverse hybridization on microbeads arrays and on biallelic SBT show that when locus-specific PCR is used for HLA typing, the second haplotype will be missed if X80% cells with aUPD are present in the blood sample. Generic primers did not allow an adequate amplification of the second allele when present in o20% of peripheral blood lymphocytes. Only when applying monoallelic SBT and PCR-SSP the second allele could be detected, although at a much lower level (Figure 1 ). Because the PCR-SSO reverse hybridization on microbeads arrays (luminex technology) is an increasingly used method for routine HLA typing of clinical samples we sought to define a threshold level for the detection of two alleles at each of the HLA-A, B, DRB1 loci. Based on DNA mixing experiments, we have estimated that the detection threshold of HLA heterozygotes was achieved when blood samples had o80% blasts. These results imply that upon typing AML patients in blastic phase one must be cautious in interpreting any result showing homozygosity in the whole HLA region or even at a single HLA locus. In the absence of aUPD, a microdeletion such as the one involving the HLA-B in patient DMF may also lead to an apparent homozygosity that would go undetected if it occurs early during the blastic transformation and if no family genotyping is performed to assess the segregation of the HLA haplotypes. In chronic myeloid leukemia patients, specific chromosomal alterations, losses and gains were unique to cases with clinically manifested or suspected accelerated/blast stage. 18 To our knowledge, this is the first study showing an aCGH pattern for patients with aUPD involving part of or the entire HLA region. The technique also revealed constitutive or de-novo microdeletions or gains at 6p21 in four of the six patients. It would be interesting to evaluate a larger set of AML patients by aCGH searching small-scale copy number variations that could possibly involve any of the HLA or non-HLA genes. HLA homozygosity could provide a selective advantage to neoplastic cells by restricting the potential of presentation of tumor-specific epitopes by HLA antigens. Interestingly, a recent study 19 has reported a slightly increased homozygosity rate at HLA-A, B, C, DRB1 loci in a large cohort of chronic lymphocytic leukemia patients compared with HLA allele distribution in the population. Copy-neutral LOH at 6p arms has recently been observed in 13% aplastic anemia patients, all involving the HLA region. A proposed mechanism for escape hematopoiesis in these patients with 6p LOH postulated that CTL autoimmunity would be biased by reducing the presentation of still unknown autoantigens by the missing HLA molecules. 20 If aUPD in AML blasts involving part of, or the entire HLA region leads to decreases T-cell immunosurveillance, then the possibility exists that haploidentical or mismatched unrelated hematopoietic stem cell transplantation donors or cord blood units could be selected on the basis of the lost HLA haplotype or HLA single antigen as detected in the pretransplant AML blasts with aUPD involving 6p21.
